View Older Stories
-
Hims and Hers (HIMS) PT Raised to $23 at Truist Securities
-
Hims & Hers launches generic semaglutide in Canada at $149 monthly
-
Hims & Hers launches generic semaglutide in Canada at $149 monthly
-
Hims and Hers (HIMS) PT Lowered to $28 at BofA Securities
-
Hims and Hers (HIMS) PT Lowered to $24.50 at Jefferies, 'execution story now'
-
Hims and Hers (HIMS) PT Lowered to $30 at BofA Securities
-
Hims & Hers stock tumbles as revenue, EBITDA miss estimates
-
BTIG on Hims and Hers (HIMS): 'will need to aggressively manage sales and marketing costs'
-
Hims and Hers (HIMS) PT Raised to $25 at TD Cowen
-
Hims and Hers (HIMS) PT Raised to $35 at Needham
-
Hims and Hers (HIMS) PT Raised to $35 at Needham
-
Hims and Hers (HIMS) PT Raised to $28 at Citi
-
Evercore ISI on Hims and Hers (HIMS): 'Prognosis Unclear'
-
Hims and Hers (HIMS) PT Raised to $32 at Canaccord
-
Hims & Hers Health, Inc. (HIMS) Misses Q1 EPS by 41c, Misses on Revenue; Offers FY26 Revenue Guidance
-
Hims & Hers earnings preview: BofA says company lost GLP-1 share in 1Q
-
Hims & Hers Health, Inc. (HIMS) call put ratio 3.4 calls to 1 put with a focus on 1K contracts of January 105 calls into quarter results
-
Truist on Hims and Hers (HIMS): 'NVO Partnership Off to a Solid Start'
-
Hims & Hers Health, Inc. (HIMS) spreader of May calls into quarter results
-
Hims & Hers Health, Inc. (HIMS) spreader of 2K contracts of May 28 and 30 calls into quarter results
-
Amazon Pharmacy adds same-day delivery for Ozempic pill
-
JPMorgan Starts Hims and Hers (HIMS) at Overweight
-
Hims and Hers (HIMS) PT Raised to $32 at BofA Securities
-
Hims & Hers expands platform to include Eli Lilly weight loss medications
-
Morgan Stanley Comments Eli Lilly (LLY) and Medicare GLP-1 Obesity Coverage
-
Amazon One Medical launches weight management program with GLP-1 drugs
-
Hims & Hers Extends Drop To 6% After Amazon Glp-1 News
-
FDA encourages testosterone therapy makers to seek low libido indication
-
Leerink Partners on Hims and Hers (HIMS): FDA meeting to discuss peptide restrictions 'clear positive,' could fill growth hole
-
Hims and Hers (HIMS) PT Raised to $25 at BofA Securities
-
Hims & Hers Health, Inc. (HIMS) Strength Tied to RFK Jr Comments on Peptides
-
Hims and Hers (HIMS) PT Lowered to $21 at BofA Securities
-
Wolfe: 'We're observing some reports of GLP-1 users refreshing their wardrobes as weight loss progresses'
-
Hims and Hers (HIMS) PT Lowered to $23 at TD Cowen
-
Canaccord on Hims and Hers (HIMS): 'Novo partnership goes live; near-term headwind to revenue, long-term tailwind to the story'
-
BofA on Hims and Hers (HIMS): '$149/month subscription fee is slightly higher than we initially expected'
-
HIMS partners with Novo Nordisk to offer FDA-approved GLP-1 medications
-
HIMS to offer Wegovy and Ozempic through partnership with Novo Nordisk
-
Street Calls of the Week
-
Hims shares set for best week on record after new Novo Nordisk deal
-
Hims & Hers hires ex-Eli Lilly PR chief Beiser as top communications officer
-
BofA Securities Upgrades Hims and Hers (HIMS) to Neutral
-
Canaccord Reiterates Buy Rating on Hims and Hers (HIMS)
-
Citi Upgrades Hims and Hers (HIMS) to Neutral
-
Hims & Hers Health, Inc. (HIMS) call put ratio 2.2 calls to 1 put as share price up 41%
-
TD Cowen: 'Wegovy Injection may be declining'
-
Needham Upgrades Hims and Hers (HIMS) to Buy
-
Nephron Upgrades Hims and Hers (HIMS) to Buy
-
BTIG Reiterates Neutral Rating on Hims and Hers (HIMS) following Novo partnership
-
Truist Reiterates Hold Rating on Hims and Hers (HIMS)

